Drug Profile


Alternative Names: ENTO; GS-9973

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator CGI Pharmaceuticals
  • Developer CGI Pharmaceuticals; Gilead Sciences
  • Class Amines; Anti-inflammatories; Antineoplastics; Antirheumatics; Imidazoles; Indazoles; Morpholines; Pyrazines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Phase I Acute lymphoblastic leukaemia; Cancer
  • No development reported Inflammation; Rheumatoid arthritis

Most Recent Events

  • 27 Feb 2017 Phase-II clinical trials in Acute myeloid leukaemia in USA (PO) (Gilead Sciences 10-K, February 2017)
  • 03 Jan 2017 OHSU Knight Cancer Institute and National Cancer Institute plan a phase I/II trial for Chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma, Follicular lymphoma, Waldenstrom's macroglobulinaemia and Mantle cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT03010358)
  • 03 Dec 2016 Updated efficacy data from a phase II trial in chronic lymphocytic leukaemia and Non-Hodgkin's lymphomapresented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016) (ADNM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top